Thesis
Splice-switching antisense oligonucleotide-mediated knockdown of ATXN2 for the potential treatment of amyotrophic lateral sclerosis
Honours, Murdoch University
2022
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease of motor neurons in the central nervous system, that often manifests from the age of 40 to 70 years and results in paralysis and death within 3 to 5 years of symptom onset (1). ALS is estimated to affect between 1.57 and 9.62 per 100,000 individuals (2). The cost of ALS in 2015 was estimated to be $2.37 billion Australia-wide, presenting a significant economic burden (3). Furthermore, the global incidence of ALS is projected to increase by 69% from 2015 to
2040, as the proportion of individuals aged over 64 is expected to rise to 16% by 2050, from 9% in 2015 (4, 5)...
Details
- Title
- Splice-switching antisense oligonucleotide-mediated knockdown of ATXN2 for the potential treatment of amyotrophic lateral sclerosis
- Authors/Creators
- Alanis Lima
- Contributors
- Sue Fletcher (Supervisor) - Murdoch University, Health Futures InstituteIanthe Pitout (Supervisor) - Murdoch University, Centre for Molecular Medicine and Innovative TherapeuticsLoren Flynn (Supervisor) - Murdoch University, Centre for Molecular Medicine and Innovative TherapeuticsAnthony Akkari (Supervisor) - Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics
- Awarding Institution
- Murdoch University; Honours
- Identifiers
- 991005546867707891
- Murdoch Affiliation
- College of Science, Health, Engineering and Education; School of Medical, Molecular and Forensic Sciences
- Resource Type
- Thesis
Metrics
83 File views/ downloads
106 Record Views